-
Biomedicine has great potential, and pharmaceutical equipment companies have made a big layout
Time of Update: 2022-10-25
As a leading enterprise of domestic pharmaceutical equipment, Dongfulong is looking at the huge potential of the biomedical market behind its large-scale increase in fundraising.
As a leading enterprise of domestic pharmaceutical equipment, Dongfulong is looking at the huge potential of the biomedical market behind its large-scale increase in fundraising.
-
The fourth dose of the new crown vaccine is coming
Time of Update: 2022-10-25
Some experts also said that because many people in China have been vaccinated with the new crown vaccine for a long time (more than 180 days), the neutralizing antibodies in the body have dropped a lot, and cellular immunity has also declined simultaneously, according to a large number of retrospective studies, various first-generation vaccines are like this, so they need to be vaccinated again to improve the level of immunity in the body.
-
Top 10 global vaccine giants, two Chinese companies on the list
Time of Update: 2022-10-25
China Sinovac and Zhifei Biotechnology Thanks to the huge revenue brought by the new crown vaccine, Sinovac's sales increased nearly 3 times in 2021, surpassing Moderna and ranking among the top three, with the new crown vaccine CoronaVac being the main driving force.
-
Expert review completed, 2022 medical insurance negotiations enter the "countdown"! A few highlights are worth paying attention to
Time of Update: 2022-10-25
The expert review has now been completed, which means that the high-profile negotiation phase is coming The list of drugs is full of highlights The list of drugs is full of highlights 343 drugs that passed the formal examination this time, including 183 new varieties of Western medicines and 15 proprietary Chinese medicines added to the catalog; There are 111 renewals of Western medicines and 34 proprietary Chinese medicines in the catalog.
-
How do companies choose CMO?
Time of Update: 2022-10-25
The global market for contract processing outsourcing is growing, with more and more scientific institutions, pharmaceutical companies and biopharmaceutical companies choosing to outsource production to CMOs and drug development and manufacturing outsourcing services (CDMOs).
-
First-line breast cancer! Hengrui "Darcili" new indication report on the market
Time of Update: 2022-10-25
The highest domestic CDK4/6 innovative drug in phase III clinical trials From: Insight Database Project Progress Module On October 20, the official website of CDE showed that Hengrui Pharmaceutical's CDK4/6 inhibitor darcilil new indication was reported on the market.
-
Grasp the lifeline of new drug research and development from a macro perspective
Time of Update: 2022-10-25
When the candidate compound enters the development stage, the physicochemical properties of the compound are characterized and the early formulation process is studied, and a drug product with certain stability, manufacturability and exhibits optimal PK (i.
-
Under the cold winter, the way Biotech survives
Time of Update: 2022-10-25
The entrepreneurial quality of the founder and the construction of modern company system Biotech companies are mostly based on technology or product research and development, lack of production, quality, marketing, sales, finance, human resources and other management systems, as a necessary step of transformation and upgrading, enterprises should establish and continuously optimize the above management system as soon as possible, the founder to complete the butterfly change from scientist to entrepreneur.
-
In 2021, the total sales of seven major categories of pharmaceutical commodities in China will exceed 2.6 trillion yuan, and the scale of China's drug circulation market has grown steadily
Time of Update: 2022-10-25
In addition, the digital transformation of the pharmaceutical circulation industry has accelerated, the number of pharmaceutical e-commerce orders has increased significantly, and China's drug supply guarantee capacity has been greatly improved.
-
Can it replace Humira as the future medicine king? The latest summary of miracle JAK inhibitors
Time of Update: 2022-10-25
There are 4 members of the tyrosine kinase (JAK) family: JAK1, JAK2, JAK3, TYK2, which play an important role in the signaling cascade of multiple type I and II cytokine receptors. The mediated signa
-
Chasen's column analyzes the current situation of CMOs of innovative drugs at home and abroad
Time of Update: 2022-10-25
CMO is the abbreviation of Chief Medical Officer, which is translated domestically as Chief Medical Officer, corresponding to the CEO translation, which means the main medical person in English. In r
-
Is it feasible to stop using animals in biomedical research?
Time of Update: 2022-10-25
com/s/MS4nZw3b_Kqo_-ZbGHBLwg Recently, the United States introduced a new bill aimed at reducing animal testing in the future.
com/s/MS4nZw3b_Kqo_-ZbGHBLwg Recently, the United States introduced a new bill aimed at reducing animal testing in the future.
-
Under the tide of reviews, there has been good news from many pharmaceutical companies in the past week
Time of Update: 2022-10-25
, Ltd. On October 14, the State Food and Drug Administration issued a new batch of drug approval documents to be received, showing that the caspofungin acetate for injection of Sino-American East China Pharmaceutical passed the consistency evaluation.
-
Roche introduced nearly $1 billion in viral immunotherapy
Time of Update: 2022-10-25
" ” Original English text: On October 20, Roche entered into a strategic collaboration and licensing agreement with Hookipa Pharma to jointly develop HB-700 and a second undisclosed novel arenavirus immunotherapy for KRAS-mutated cancers.
-
A large number of pharmaceutical companies report good news in the third quarter, and this field may become a big winner
Time of Update: 2022-10-25
Among them, BGI Intelligent Manufacturing and CapBiotech expect the net profit attributable to the parent in the first three quarters of this year to increase by 340% and 124% year-on-year, respectively.
-
Under the background of the transformation and upgrading of the pharmaceutical industry, the "slimming" of domestic and foreign pharmaceutical companies will accelerate
Time of Update: 2022-10-25
It is understood that Kyushu Pharmaceutical will invest 185 million yuan in the CDMO (contract customized R&D and production) preparation project of Siwei Pharmaceutical to acquire 100% of the equity of Sandoz (China) Zhongshan Preparation Factory and increase the capital, of which 15.
-
The first copy of stone medicine was approved to be sued, and the East Sunshine patent challenge was successful, what is the difference between the two?
Time of Update: 2022-10-25
Interestingly, another anti-influenza drug company, East Sunshine, issued an announcement today (October 19): The self-developed fingolimod capsules have been successfully challenged for the first generic patent and have been approved for marketing in the United States.
-
Within 3 days, the cooperation of 3.5 billion yuan and 2.2 billion US dollars was officially announced, how did this company do it?
Time of Update: 2022-10-25
With the development of omics technology, information technology, gene technology and in-depth study of disease biology, the rational design, virtual screening, high-throughput synthesis, structural
-
The development of China's pharmaceutical industry is analyzed from the differences in biotech commercialization models between China and the United States
Time of Update: 2022-10-25
Policy Research Center, China Association for the Promotion of Pharmaceutical Innovation Policy Research Center, China Association for the Promotion of Pharmaceutical Innovation Author: Zhang Yangyan
-
$1.76 billion! Gilead and MacroGenics entered into a CD123/CD3 bispecific antibody licensing agreement
Time of Update: 2022-10-25
Original English text: MGD024 is a second-generation CD123 x CD3 DART molecule developed through MacroGenics' DART® platform and is designed to extend half-life and reduce cytokine release, making it suitable for intermittent dosing.
